Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylprednisolone + vitamin D3 is a combination of two agents: - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts by binding to the glucocorticoid receptor, modulating gene expression to suppress pro-inflammatory cytokines and immune cell activity. It is used in the treatment of various autoimmune, inflammatory, allergic, respiratory, hematologic, neoplastic, dermatologic, gastrointestinal, ophthalmic disorders and more. - **Vitamin D3 (cholecalciferol)** is a fat-soluble secosteroid that enhances intestinal absorption of calcium and phosphate. It plays an essential role in bone health by promoting calcium homeostasis and has immunomodulatory effects via the vitamin D receptor (VDR). This combination may be considered for patients at risk of corticosteroid-induced osteoporosis or deficiency states; however, there are clinically significant interactions between these drugs. Methylprednisolone can reduce absorption/metabolism of vitamin D3 and decrease its efficacy; conversely, adequate supplementation with calcium/vitamin D may help prevent steroid-induced bone loss[1][2][7]. The interaction requires careful monitoring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylprednisolone + vitamin D3.